Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGrenader, Tal
dc.contributor.authorPavel, Marianne E.
dc.contributor.authorRuszniewski, Philippe B.
dc.contributor.authorĆwikła, Jarosław B.
dc.contributor.authorPhan, Alexandria T.
dc.contributor.authorRaderer, Markus
dc.contributor.authorCapdevila Castillon, Jaume
dc.date.accessioned2021-10-29T07:38:42Z
dc.date.available2021-10-29T07:38:42Z
dc.date.issued2020-03
dc.identifier.citationGrenader T, Pavel ME, Ruszniewski PB, Ćwikła JB, Phan AT, Raderer M, et al. Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors. Anticancer Drugs. 2020 Mar;31(3):216–22.
dc.identifier.issn0959-4973
dc.identifier.urihttp://hdl.handle.net/11351/6483
dc.descriptionProgression-free survival; Neuroendocrine tumors
dc.description.abstractAccessible prognostic tools are needed to individualize treatment of neuroendocrine tumors (NETs). Data suggest neutrophil/lymphocyte ratios (NLRs) have prognostic value in some solid tumors, including NETs. In the randomized double-blind CLARINET study (NCT00353496; EudraCT 2005-004904-35), the somatostatin analog lanreotide autogel/depot increased progression-free survival (PFS) compared with placebo in patients with inoperable or metastatic intestinal and pancreatic NETs (grades 1–2, Ki-67 < 10%). The exploratory post-hoc analyses presented here evaluated the prognostic value of NLR in the CLARINET study cohort, in the context of and independently from treatment. Kaplan–Meier PFS plots were generated for patients with available NLR data, in subgroups based on NLR values, and 24-month survival rates were calculated. P values and hazard ratios for prognostic effects were generated using Cox models. 31216222 Baseline characteristics were balanced between lanreotide autogel/depot 120 mg (n = 100) and placebo (n = 101) arms. Irrespective of treatment, raw 24-month PFS rates were comparable across subgroups based on NLR tertiles [37.3% (low), 38.8% (middle), 38.8% (high); n = 67 per group] and NLR cutoff of 4 [38.1% (NLR ≤ 4; n = 176), 40.0% (NLR > 4; n = 25)]. Furthermore, NLRs were not prognostic in Cox models, irrespective of subgroups used. The therapeutic effect of lanreotide autogel/depot 120 mg was independent of NLRs (P > 0.1). These exploratory post-hoc analyses in patients with advanced intestinal and pancreatic NETs contrast with previous data suggesting NLR has prognostic potential in NETs. This may reflect the inclusion of patients with lower-grade tumors or use of higher NLR cutoff values in the current analysis.
dc.language.isoeng
dc.publisherWolters Kluwer Health
dc.relation.ispartofseriesAnti-Cancer Drugs;31(3)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectTumors neuroendocrins - Prognosi
dc.subject.meshNeuroendocrine Tumors
dc.subject.meshPrognosis
dc.titlePrognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1097/CAD.0000000000000909
dc.subject.decstumores neuroendocrinos
dc.subject.decspronóstico
dc.relation.publishversionhttps://doi.org/10.1097/CAD.0000000000000909
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Grenader T] Oncology Institute, Leumit Health Services, Jerusalem, Israel. [Pavel ME] Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Charité University Medicine Berlin, Berlin, Germany. Department of Endocrinology, Friedrich Alexander University Erlangen-Nuernberg, Erlangen, Germany. [Ruszniewski PB] Department of Gastroenterology-Pancreatology, Beaujon Hospital, Clichy, France. [Ćwikła JB] Department of Radiology, University of Varmia and Masuria, Olsztyn, Poland. [Phan AT] Hematology, Oncology & Radiation Oncology, University of Texas Health Science Center at Tyler, Tyler, Texas, USA. [Raderer M] Department of Oncology, University Hospital, Vienna, Austria. [Capdevila J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid31977567
dc.identifier.wos000528817300003
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record